US Pharma MarketingCancer biotech Parabilis ups IPO plans to potentially record-setting $637M
Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, with a whopping $625 million, Parabilis Medicines has upsized its own IPO plans with the potential to eclipse that record.
Source: FierceBiotech